KLSE (MYR): KOSSAN (7153)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
1.82
Today's Change
0.00 (0.00%)
Day's Change
1.80 - 1.84
Trading Volume
3,375,800
Market Cap
4,655 Million
NOSH
2,558 Million
Latest Quarter
30-Jun-2024 [#2]
Announcement Date
22-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
15-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
-0.36% | 1,050.30%
Revenue | NP to SH
1,685,158.000 | 104,570.000
RPS | P/RPS
65.88 Cent | 2.76
EPS | P/E | EY
4.09 Cent | 44.52 | 2.25%
DPS | DY | Payout %
2.00 Cent | 1.10% | 48.80%
NAPS | P/NAPS
1.51 | 1.21
QoQ | YoY
49.53% | 1642.1%
NP Margin | ROE
6.38% | 2.71%
F.Y. | Ann. Date
30-Jun-2024 | 22-Aug-2024
Latest Audited Result
31-Dec-2023
Announcement Date
24-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
24-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Revenue | NP to SH
1,585,878.000 | 14,222.000
RPS | P/RPS
62.00 Cent | 2.94
EPS | P/E | EY
0.56 Cent | 327.33 | 0.31%
DPS | DY | Payout %
2.00 Cent | 1.10% | 358.83%
NAPS | P/NAPS
1.50 | 1.21
YoY
-90.92%
NP Margin | ROE
1.08% | 0.37%
F.Y. | Ann. Date
31-Dec-2023 | 22-Feb-2024
Revenue | NP to SH
1,763,058.000 | 125,790.000
RPS | P/RPS
68.93 Cent | 2.64
EPS | P/E | EY
4.92 Cent | 37.01 | 2.70%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-0.02% | 328.27%
NP Margin | ROE
7.28% | 3.27%
F.Y. | Ann. Date
30-Jun-2024 | 22-Aug-2024
Last 10 FY Result | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1,763,058 | 1,685,158 | 1,585,878 | 2,316,228 | 6,657,487 | 3,653,514 | 2,221,607 | 2,144,235 | 1,957,445 | 1,667,996 | 1,639,509 | 1,301,740 | 2.21% | |
PBT | 159,106 | 131,945 | 35,846 | 212,889 | 3,747,770 | 1,444,631 | 280,107 | 249,329 | 229,606 | 210,008 | 268,567 | 186,721 | -16.74% | |
Tax | -30,726 | -24,364 | -18,688 | -53,581 | -890,922 | -352,019 | -52,185 | -44,029 | -44,023 | -38,960 | -62,248 | -37,885 | -7.54% | |
NP | 128,380 | 107,581 | 17,158 | 159,308 | 2,856,848 | 1,092,612 | 227,922 | 205,300 | 185,583 | 171,048 | 206,319 | 148,836 | -21.32% | |
- | ||||||||||||||
NP to SH | 125,790 | 104,570 | 14,222 | 156,619 | 2,853,548 | 1,087,090 | 224,783 | 200,784 | 185,583 | 172,003 | 202,530 | 145,597 | -22.76% | |
- | ||||||||||||||
Tax Rate | 19.31% | 18.47% | 52.13% | 25.17% | 23.77% | 24.37% | 18.63% | 17.66% | 19.17% | 18.55% | 23.18% | 20.29% | - | |
Total Cost | 1,634,678 | 1,577,577 | 1,568,720 | 2,156,920 | 3,800,639 | 2,560,902 | 1,993,685 | 1,938,935 | 1,771,862 | 1,496,948 | 1,433,190 | 1,152,904 | 3.47% | |
- | ||||||||||||||
Net Worth | 3,852,435 | 3,852,435 | 3,839,167 | 3,883,565 | 4,032,672 | 2,380,611 | 1,419,618 | 1,291,725 | 1,151,042 | 104,234,019 | 946,412 | 799,393 | 19.03% |
Equity | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Worth | 3,852,435 | 3,852,435 | 3,839,167 | 3,883,565 | 4,032,672 | 2,380,611 | 1,419,618 | 1,291,725 | 1,151,042 | 104,234,019 | 946,412 | 799,393 | 19.03% | |
NOSH | 2,557,872 | 2,557,872 | 2,557,872 | 2,557,872 | 2,557,872 | 2,557,872 | 1,278,936 | 1,278,936 | 639,468 | 639,472 | 639,468 | 639,515 | 16.64% |
Ratio Analysis | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NP Margin | 7.28% | 6.38% | 1.08% | 6.88% | 42.91% | 29.91% | 10.26% | 9.57% | 9.48% | 10.25% | 12.58% | 11.43% | - | |
ROE | 3.27% | 2.71% | 0.37% | 4.03% | 70.76% | 45.66% | 15.83% | 15.54% | 16.12% | 0.17% | 21.40% | 18.21% | - |
Per Share | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RPS | 69.10 | 66.04 | 62.15 | 90.77 | 260.84 | 142.83 | 173.71 | 167.66 | 306.11 | 260.84 | 256.39 | 203.55 | -12.34% | |
EPS | 4.92 | 4.10 | 0.56 | 6.14 | 111.80 | 42.50 | 17.58 | 15.70 | 28.77 | 26.13 | 31.67 | 22.77 | -33.73% | |
DPS | 0.00 | 2.00 | 2.00 | 2.50 | 48.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.50 | 0.00 | - | |
NAPS | 1.5098 | 1.5098 | 1.5046 | 1.522 | 1.58 | 0.9307 | 1.11 | 1.01 | 1.80 | 163.00 | 1.48 | 1.25 | 2.07% |
Adjusted Per Share Value based on latest NOSH - 2,557,872 | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RPS | 68.93 | 65.88 | 62.00 | 90.55 | 260.27 | 142.83 | 86.85 | 83.83 | 76.53 | 65.21 | 64.10 | 50.89 | 2.21% | |
EPS | 4.92 | 4.09 | 0.56 | 6.12 | 111.56 | 42.50 | 8.79 | 7.85 | 7.26 | 6.72 | 7.92 | 5.69 | -22.69% | |
DPS | 0.00 | 2.00 | 2.00 | 2.49 | 47.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.37 | 0.00 | - | |
NAPS | 1.5061 | 1.5061 | 1.5009 | 1.5183 | 1.5766 | 0.9307 | 0.555 | 0.505 | 0.45 | 40.7503 | 0.37 | 0.3125 | 19.03% |
Price Multiplier on Financial Quarter End Date | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date | 28/06/24 | 28/06/24 | 29/12/23 | 30/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 29/12/17 | 30/12/16 | 31/12/15 | 31/12/14 | - | |
Price | 2.35 | 2.35 | 1.85 | 1.10 | 1.92 | 4.50 | 4.16 | 4.34 | 8.11 | 6.59 | 9.30 | 4.47 | - | |
P/RPS | 3.40 | 3.56 | 2.98 | 1.21 | 0.74 | 3.15 | 2.39 | 2.59 | 2.65 | 2.53 | 3.63 | 2.20 | 3.42% | |
P/EPS | 47.67 | 57.34 | 331.92 | 17.92 | 1.72 | 10.59 | 23.67 | 27.64 | 27.94 | 24.50 | 29.36 | 19.63 | 36.89% | |
EY | 2.10 | 1.74 | 0.30 | 5.58 | 58.23 | 9.44 | 4.22 | 3.62 | 3.58 | 4.08 | 3.41 | 5.09 | -26.97% | |
DY | 0.00 | 0.85 | 1.08 | 2.27 | 25.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.59 | 0.00 | - | |
P/NAPS | 1.56 | 1.56 | 1.23 | 0.72 | 1.22 | 4.84 | 3.75 | 4.30 | 4.51 | 0.04 | 6.28 | 3.58 | -11.18% |
Price Multiplier on Announcement Date | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date | 22/08/24 | 22/08/24 | 22/02/24 | 16/02/23 | 17/02/22 | 17/02/21 | 21/02/20 | 19/02/19 | 22/02/18 | 23/02/17 | 23/02/16 | 25/02/15 | - | |
Price | 2.04 | 2.04 | 2.02 | 1.13 | 1.69 | 4.01 | 4.65 | 4.00 | 8.70 | 6.48 | 6.75 | 5.50 | - | |
P/RPS | 2.95 | 3.09 | 3.25 | 1.24 | 0.65 | 2.81 | 2.68 | 2.39 | 2.84 | 2.48 | 2.63 | 2.70 | 2.08% | |
P/EPS | 41.38 | 49.78 | 362.42 | 18.41 | 1.51 | 9.44 | 26.46 | 25.48 | 29.98 | 24.09 | 21.31 | 24.16 | 35.08% | |
EY | 2.42 | 2.01 | 0.28 | 5.43 | 66.15 | 10.60 | 3.78 | 3.92 | 3.34 | 4.15 | 4.69 | 4.14 | -25.85% | |
DY | 0.00 | 0.98 | 0.99 | 2.21 | 28.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.81 | 0.00 | - | |
P/NAPS | 1.35 | 1.35 | 1.34 | 0.74 | 1.07 | 4.31 | 4.19 | 3.96 | 4.83 | 0.04 | 4.56 | 4.40 | -12.36% |
PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
All figures in '000 unless specified.
The number fren, where n when is the QR please since repeated so many times. I trusted u tho
1 week ago
Clade I MPOX is much more dangerous and transmissible this time around. Unlike Clade II, Clade I can spread without sexual contact, making it much easier to transmit through skin-to-skin contact.
It is significantly more dangerous and contagious.
1 week ago
Mpox will not be pandemic like Covid.. and we want that. If it's a pandemic, US might delay the tariff on China. This will strengthen CHina glove financially. We want Mpox not a pandemic and US implement their tariff on China gloves as soon as possible.
1 week ago
Mpox is going to be worse than Covid pandemic because of the incubation period 21 days lol
1 week ago
Countries across Asia are increasing surveillance and countermeasures against mpox as Thailand reported its first suspected case of a new, more dangerous variant of the virus.
South Korea said that epidemiologists and public health doctors will be deployed at the gates of flights arriving from Ethiopia to monitor incoming passengers.
Anyone with mpox symptoms will be required to report to quarantine officers on arrival.
Waste from aircraft toilets will also be monitored for the virus.
Source: Telegraph
1 week ago
But don't worry, I believe revenue drop could be highly due to the Red Sea crisis and cause some of the June'24 sales postpone to July'24.
If this is the case, then you can expect next quarter Q3'2024 to achieve PAT of minimum RM70-80mil (assume at least RM10mil profit brought forward from Q2 to Q3)
1 week ago
I hope you're right Albukhary. With this QR result it could go either way. Just bcoz Harta QR was excellent. Kossan is showing no improvement from previous qtr.
1 week ago
Harta PBT margin 7%
Kossan (gloves division) PBT margin 6.26%
and yes theres some shipment delays ( not sure how much , but harta had around 10% sales volume delay )
unless your expectation was not realistic if not its within the line
1 week ago
Harta profit 31.9Mill .. price 2.75. What do you said abt that?
Endgame
31 mil profit, no wonder dropped from 2.5x to 2.0x
1 week ago
Harta:
Mar’24 : Revenue 529.83mil
Mar’24 : PBT 18.88mil
Mar’24 : PBT Margin 3.6%
Jun’24 : Revenue 583.84mil
Jun’24 : PBT 41.14mil
Jun’24 : PBT Margin 7.0%
Kossan:
Mar’24 : Revenue 451.63mil
Mar’24 : PBT 40.98mil
Mar’24 : PBT Margin 9.0%
Jun’24 : Revenue 429.91mil
Jun’24 : PBT 38.57mil
Jun’24 : PBT Margin 9.0%
1 week ago
@beginner888
for kossan you have to sort out the gloves division part
its 6.26% instead of 9.0%
1 week ago
@Patron
"Sorting out glove division part" is like saying saying McD has to sort out the burger part from the fries part.
IF that's the case then Harta has to "sort out" their COAT gloves from the nitrile and latex gloves. Cmmon. Don't be ridiculous.
1 week ago
Analysts upgrade Kossan's ratings after 1H results meet expectations. Nice ~
https://theedgemalaysia.com/node/723968
1 week ago
Have to hold longer, no concern next few qtrs, just no easy money, unless ustr pull in the tariffs to 2025. Or set it to 50 percent as propose
1 week ago
@Patron noted. I missed your comment in the bracket (i.e., gloves division). Thank you for the reminder.
1 week ago
@Chipee
you know Kossan's non glove division for eg. Technical Rubber division contributed only 10% of the overall revenue but it contributed almost 30% of its PBT right ?
theres no right way to have 100% apple to apple comparison but we try to close the gap as much as possible to see the clearer picture
1 week ago
@beginner888
Harta & Kossan have similar PBT margin % if you exclude non cash / non operating cost like impairment , decommissioning cost , ramp up cost and etc.
its at 6-7% in Q2 - not too bad but not impressive enough. it all depends on upcoming sales order momentum.
1 week ago
@kimsua
USTR tariff will be implemented in 2026 - not too far away actually ( about 16 months away )
consider the long lead time and shipment time from China firms
probably the orders will come to Malaysia as soon as Q2 2025
1 week ago
@patron the final ustr 301 determination has been delayed until the end of August. They are negotiating and getting feedback, one of the proposal is a 50 percent in medical ppe in 2025 while relaxing critical syringes tariffs. This is based after feedback from both medical associations and manufactures associations. Let's see how. Will scout around and published as soon as I can.
1 week ago
Ops expenses reduce 430k to 409k. Trade receivable flat qtq but 30k higher than 2023. Red Sea is not really a big problem. Most expect better revenue. Best operating margin, well manage but can they manage the sales volume. If flat again next quarter, time to reasses. USTR should have a statement end of the week or next week
1 week ago
@kimsua
for Harta ,
Q2 sales volume at 5.9b
but 0.6b was delayed
it means 10% of the revenue was not recognized , which i think was quite serious especially the margin is at razor thin now
6 days ago
Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24
Harta's Sales volume (bil pieces) 5.7 4.3 4.6 4.5 5.6 5.9
Q3 is expected to be at 2.2b per month ( 6.6b per Qr)
volume is increasing but ASP is quite flattish i guess the industry wide is still facing oversupply issue but we are near to equilibrium as Harta / Kossan are no longer in losses anymore
demand < supply = losses
demand = supply = slight/zero profit
demand > supply = profit
its just part of the cycle
6 days ago
The Global Strategic Preparedness and Response Plan (SPRP) for mpox, from September 2024 to February 2025, outlines urgent global actions to combat a new mpox outbreak declared a public health emergency. Focused on controlling human-to-human transmission, the plan emphasizes surveillance, research, and equitable access to medical tools, with an initial budget of $135 million.
5 days ago
The WHO is taking strong measures to stop the spread of Mpox. With only two confirmed cases of the more dangerous strain outside of Africa, they are already implementing a six-month readiness and preparedness program.
The WHO actions suggest an explosion of Mpox cases are imminent.
5 days ago
Kenanga share got short kaw kaw ... hahaha ..
This IB always down play glove stock. Happy their stocks get trashed. The trashing will continue after the suspension. 😂
https://www.thestar.com.my/business/business-news/2024/08/29/bursa-malaysia-suspends-idss-for-kenanga-investment-bank
2 days ago
More tariff is coming ... Canada. Hopefully they target on gloves too and EU follow suit.
https://insidetrade.com/trade/our-most-read-canada-targets-chinese-evs-steel-and-aluminum-hints-more-come
2 days ago
Yeah ... F them big time. 😂
ChandranG
What goes around, come around. Your turn to get shorted, Kenanga 😁
2 days ago
Who collect Kossan in August, i wish to congratulate you all, because next month Sep is Kossan "party time", wait for it.
1 day ago
Who sell one, i also hope you don't be sad, absolutely you're not entitled for this.
1 day ago
5231428
Looks very promising closing at high.
1 week ago